In recent decades, management of prostate and breast cancer patients has changed considerably. The purpose of our study is to interpret patterns of prostate and breast cancer incidence and mortality in four Nordic countries across age groups and time periods. Prostate and breast cancer incidence and mortality data were obtained from the NORDCAN database. Joinpoint regression models were used to identify changes in the trends. A more prominent increase in prostate than breast cancer incidence was observed. From the mid-1990s, mortality rates in patients below 75 years of age have decreased for both cancers in all four countries. The relative decline in breast cancer mortality from 1985-1989 to 2009-2013 were largest in women under 50 years of age, with reductions in mortality rates ranging from 38% in Finland to 55% in Denmark. In the age group 55-74 years, mortality rates for prostate cancer declined more than for breast cancer in all countries except Denmark, ranging from 14% in Denmark to 39% in Norway. The substantial decrease in breast cancer mortality in women below regular screening age and the reductions in mortality from both cancers in Denmark from the mid-1990s are consistent with beneficial contributions from improved treatment besides mammography screening and increased PSA testing. Alongside similar mortality decreases, the larger increases in prostate cancer incidence as compared to breast cancer indicate that a higher proportion of prostate cancer cases are overdiagnosed.
Introduction
In recent years, trend analyses have shown declining population-based mortality rates for both prostate and breast cancer in many countries. 1, 2 However, the extent to which the reduction in mortality can be attributed to changes in screening and treatment practices remains uncertain. Randomized studies and evaluations of the potential effects of mammography screening and prostate-specific antigen testing, have concluded with approximately 20-30% disease-specific mortality reductions for both diseases, with higher estimates of overdiagnosis for prostate cancer than for breast cancer. [3] [4] [5] Since the early to mid-1990s, organized population-based screening programs for breast cancer are implemented and extensive opportunistic PSA testing has been performed in all Nordic countries. 6 The introduction of a new screening method would be expected to cause increases in incidence most noticeable in those age groups and periods with the largest changes in diagnostic intensity, to be followed, if effective, by reductions in mortality in the corresponding and older age groups. For prostate cancer in particular, it has been suggested that cause of death registration is less reliable in the highest age categories. 7, 8 Thus, analyzing incidence and mortality trends by age may add important information for better understanding the effects of earlier diagnosis and treatment on Nordic mortality rates for prostate and breast cancer. In our study, data from the NORDCAN database for the period 1975-2013 were extracted and analyzed to provide an updated description of temporal prostate and breast cancer incidence and mortality trends by age in four Nordic countries. 9 Furthermore, we wanted to interpret these patterns across countries, time periods and age groups in relation to known changes in screening policies and treatment.
Material and Methods
Age-adjusted incidence rates per 100,000 person-years (age groups: <50, 50-69, 70-79, 801, all ages) and mortality rates (age groups: <55, 55-74, 75-84, 851, all ages) for prostate and breast cancer were obtained from the NORDCAN database for the period 1975-2013 in Denmark, Finland, Norway and Sweden. 9 As only minor reductions in mortality are expected in the first years after introduction of a new screening method, the age limit was set 5 years higher for mortality than for incidence to avoid small mortality numbers in the lowest age category. The Nordic standard population was used for age-standardized rates. 9 Unique national identification numbers in each of the Nordic countries facilitate the use of matched data from multiple sources, yielding almost complete coverage of cancer incidence and mortality rates. [10] [11] [12] [13] We depicted the age-adjusted prostate and breast cancer incidence and mortality rates to describe the long-term trends in the four countries. In addition, joinpoint regression was used to evaluate changes in incidence and mortality trends for the period 1975-2013 across age groups and countries.
14 Computation of calendar years exhibiting significant changes in the overall linear trend was based on best fitting regression models, allowing for a maximum of five joinpoints, and annual percentage change was estimated for each joined line segment. As multiple tests were performed, the significance level of each test was adjusted to control overall type I error at a specified a level of 0.05. For prostate cancer, rates in the youngest age group were excluded from the joinpoint analyses because of the small number of cases.
To compare the total change in incidence and mortality rates across countries and age groups, percentage changes between two 5-year periods were calculated. The period 1980-1984 was selected as a baseline for incidence prior to any likely significant impact of PSA testing or mammography screening. The period 1985-1989 was chosen as a baseline for mortality to capture the main mortality decreases for both cancers across countries and age groups.
To enhance the interpretation of possible variations in mortality trends, 5-year relative survival estimates for prostate and breast cancer by age (<50, 50-69, 70-79, 801) were also obtained from the NORDCAN database for the 5-year periods 1975-1979, 1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-2004, 2005-2009 and 2010-2014 .
Results

Prostate cancer incidence trends, all ages combined
During the late 1970s and the 1980s, a parallel increase in prostate cancer incidence rates was observed in all four countries ( Fig. 1 ; Table 1 ). Around 1990, prompt increases occurred in Norway and Finland, followed approximately five years later by similar increases in Denmark and Sweden. The increase from the early 1980s to the second decade of this millennium represents an approximate doubling of rates in Denmark, Finland and Norway and a 60% increase in Sweden (Table 2 ). More recently, incidence rates in the four countries have either declined (Denmark, Finland and Sweden) or stabilized (Norway). Incidence rates in Denmark were lower than in the other countries for almost the entire study period.
Trends in prostate cancer incidence by age
In all the Nordic countries, the largest and most rapid increases in prostate cancer incidence were seen in men aged 70 and younger ( Fig. 2a ; Table 2 ). In the age group 50-69, rates have increased by a factor of three to four from the early 1980s to the end of the study period, with rapid annual increases in incidence rates from 1990 in Finland and Norway, from 1995 in Sweden and from 1997 in Denmark (Table 3 ). In the older age groups, increases in incidence can be observed until the beginning of this millennium, most notably in Finland from the early and Denmark from the mid-1990s.
Prostate cancer mortality trends, all ages combined
After a period of gradually increasing prostate cancer mortality rates during the 1980s and early 1990s, significant annual declines of 1.9-2.7% were observed from the mid-to late1990s in all countries except Denmark, where rates stabilized from about 2000 ( Fig. 1 ; Table 1 ). Total change in mortality from 1985-1989 to 2009-2013 ranged from a 22% decrease in Finland to an 8% increase in Denmark (Table 2) . Prostate cancer mortality rates have stabilized or decreased 4-9 years after the most significant rises in incidence, declining first in the countries with the earliest increases in incidence.
Trends in prostate cancer mortality and survival by age
In all four countries, decreases in prostate cancer mortality were largest in the youngest age groups (Table 2 ). In men younger than 55, mortality declined between 1985-1989 and 2009-2013 , ranging from 33% in Finland to 50% in Denmark. In the age group 55-74, the mortality decreases between the same periods ranged from 14% in Denmark to What's new? In the Nordic countries, mortality rates for both prostate and breast cancer have decreased since the mid-1990s. The decline in breast cancer mortality was largest in women below regular screening age (<50 years). In the age group 55-74 years, mortality rates for prostate cancer declined more than for breast cancer in all countries except Denmark. These results are consistent with favorable contributions from advances in treatment, in addition to mammography screening and increased prostatespecific antigen testing. 39% in Norway. In the latest years of the study period, annual decreases in the age group 55-74 ranged from 1.9% in Denmark to 4.8% in Sweden (Fig 2a; Table 4 ). In contrast, among men aged 85 and older, mortality rates in Denmark have increased by 1.6% annually in recent years; only Finland has experienced any noteworthy reduction in mortality rates. In Norway and Sweden, sudden but transitory annual increases were observed in prostate cancer mortality rates (10.2% from 1990 and 5.2% from 1995, respectively). In Finland, Norway and Sweden, there was a 7-to 9-year time lag between a rapid rise in incidence in the 50-69 age group and the most notable subsequent reductions in mortality in the 55-74 age group. In Denmark, mortality rates began to decrease before any notable increase in incidence.
The 5-year relative survival rate increased rapidly in all countries and age groups between 1975-1979 and 2010-2014 , with the earliest increases in men aged 50-79 in Norway, Sweden and Finland (Fig. 3) .
Breast cancer incidence trends, all ages combined
Breast cancer incidence has increased in all four countries during the study period ( Fig. 1; Table 5 ), ranging from a Table 2 ). The most rapid increases were observed from the mid-to late-1980s in Finland and Sweden, from the mid-1990s to the early millennium years in Norway, and from 2006 to 2009 in Denmark (Table 5) . A temporary and less noticeable decrease was observed in Norway up to about 2008. In Denmark, after the peak at the end of the first decade of this millennium, incidence rates showed a marked decrease. Incidence rates were higher in Denmark than in the other countries for almost the entire study period.
Trends in breast cancer incidence by age
In the 50-69 age group, the increases in incidence of breast cancer ranged from 60% in Sweden to more than a doubling in (Fig 2b; Table 3 ). In Denmark, Norway and Sweden, incidence rates in women younger than 50 years have gradually increased (by 0.3-0.9% annually) throughout the study period. In Finland, incidence rates for women younger than 50 years increased relatively rapidly until the mid-1990s before stabilizing in subsequent years. In Denmark and Finland, moderate increases were observed in the older age group; rates in Norway and Sweden have been relatively stable throughout the study period.
Breast cancer mortality trends, all ages combined
In the late 1980s, breast cancer mortality rates in Denmark were approximately 60% higher than in the other countries, and although rates have converged somewhat in recent years, Danish figures remain 30-35% higher. In Denmark and Norway, relatively stable mortality rates during the 1980s and early 1990s were followed by significant annual declines of 2.2-2.5% from the mid-1990s ( Fig. 1 ; Table 5 ). In Sweden, mortality rates have gradually decreased over the study period, with a similar decrease in Finland from the late 1980s. From 1985-1989 to 2009-2013, total decrease in mortality ranged from 32% in Norway to 17% in Finland (Table 2) .
Trends in breast cancer mortality and survival by age
In all four countries, declining breast cancer mortality rates are most noticeable in the youngest age groups ( Fig. 2b ; Table 2 ). In women younger than 55 years, the decline in mortality between 1985-1989 and 2009-2013 ranged from 33% in Finland (38% in women <50) to 55% in Denmark. 
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Breast cancer mortality In the age group 55-74, declining mortality in the same period ranged from 11% in Finland to 33% in Norway. In the latest years of the study period, the annual decline in mortality for this age group ranged from 0.5% in Finland to 9% in Denmark (Table 4 ). The trends have been less favorable in older age groups. Five-year relative survival increased substantially in all age groups from 1975-1979 to 2010-2014 and has been increasing almost as rapid among women younger than 50 as among those aged 50-69 years (Fig. 3) . Five-year relative survival estimates for the 50-69 age group surpass those for women younger than 50 years in the period [1985] [1986] [1987] [1988] [1989] Comparison between prostate and breast cancer incidence and mortality trends Following the rise in early diagnostic activities in the 1980s and 1990s, the increases in incidence rates were much steeper for prostate cancer than for breast cancer.
Alongside similar reductions in mortality rates for prostate and breast cancers, incidence rates for prostate cancer in Nordic men aged 50-69 increased by more than double the increase in breast cancer incidence rates. For both cancers, the observed decreases in mortality are most noticeable in the youngest age group. In the 55-74 age group, the decline in mortality for prostate cancer is larger than for breast cancer in all countries other than Denmark. In Denmark, hardly any improvement has been observed in either prostate or breast cancer mortality rates in the oldest age group, and mortality trends have been less favorable above 75 years in all four countries for both cancers. In men aged 70-79, prostate cancer incidence rates have increased more rapidly than breast cancer incidence among women in the same age group.
Discussion
In the Nordic countries, organized national breast cancer screening programs are implemented and high attendance rates are achieved, whereas opportunistic PSA-testing is performed for prostate cancer. Despite this, the upsurges in ancer Epidemiology
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incidence rates following the increases in early diagnostic activities during the 1980s and 1990s were much steeper for prostate cancer. In all four Nordic countries included in our study, the observed decreases in mortality rates from the mid-1990s for both cancers are most noticeable in the youngest age group. In women aged 55 or younger, the reductions in breast cancer mortality from the late 1980s until the beginning of the present decade were largest in Denmark. Nevertheless, Denmark's total breast cancer mortality rates remain 30-35% higher than those in the other three countries. In the 55-74 age group, the decline in mortality rates was greater for prostate than for breast cancer in all countries, except Denmark. There are several possible explanations for the observed reductions in prostate and breast cancer mortality. For each cancer, we discuss three main factors that may have appeared separately or in combination:
Increased early diagnostic efforts combined with effective early treatment. Increased or more effective treatment. Changes in underlying risk factors.
Mortality reductions attributable to the introduction of a new diagnostic program or test that entails earlier detection, are expected to be most visible in the age category corresponding to or higher than the category in which the test was introduced. Thus, mortality reductions potentially caused by PSA testing or mammography screening should be lower within age categories minimally exposed to the new diagnostic methods. Furthermore, as cancer treatment intensity 15 any beneficial effects of new treatment options tend to be largest in younger age groups. While changes in the distribution of risk factors may have also impact on mortality trends in the Nordic countries, it is almost impossible to evaluate such changes by observing incidence trends over decades with increasing diagnostic intensity. Nevertheless, concurrent and continuous increases in prostate and breast cancer incidence rates, even in periods and countries with limited screening activities supports the view that the major proportion of the decline in mortality is not driven by favorable changes in risk factors.
Prostate cancer
Increased early diagnostic efforts combined with early effective treatment. After becoming available in the Nordic countries around 1990, increased PSA testing was associated with considerable upsurges in prostate cancer incidence. 6 In the ERSPC trial, relative rates of death between the screening and control groups diverged after 7-8 years. 3 In our study, the time lag between the rapid rise in incidence among men aged 50-69 and noticeable subsequent reductions in mortality among men aged 55-74 was 7-9 years in Finland, Norway and Sweden. The present results are therefore consistent with the effect of increased PSA testing and subsequent beneficial treatment of earlier diagnosed cases in three of the four countries. However, in Denmark, where PSA testing remained limited and curative radical prostatectomy for localized prostate cancer was not introduced until 1995, 16 the decline in mortality among men younger than 75 years occurred before any substantial observed change in incidence rates. Consequently, factors other than PSA testing and subsequent early treatment must have been responsible for the initial years with favorable mortality trends in Denmark. In conjunction with the fact that very few PSA-detected cancers were treated before 1995 in the other Nordic countries, 17, 18 these results suggest that other factors have also influenced the mortality trends favorably as early as in the mid-1990s. Nevertheless, our results, mainly showing that the time lags between introduction of widespread PSA testing and declining mortality conforms to what is expected from randomized studies, the present findings suggest that the recent declining mortality trends can in part be attributed to earlier diagnosis and effective early curative treatment.
Increased or more effective treatment options. Although changes in the management of prostate cancer, including the 
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increased use of radical treatment for localized disease, may have contributed to reducing mortality, 19 the impact of radical treatment on mortality trends in the Nordic countries during the 1990s is thought to be limited. 6 Improved treatment of clinically detected, locally advanced prostate cancer cases, including amplified use of higher radiotherapy doses and adjuvant hormonal treatment, 20 may also have contributed to the initial decline in mortality rates. In addition, the favorable effects of treatment for non-curable patients may have influenced these trends. The introduction of gonadotropin-releasing hormone agonists around the same time as PSA testing entailed a two-to threefold increase in annual sales of antiandrogens and gonadotropin-releasing hormone agonists from 1995 to 2000 in Sweden, Norway and Finland. 6 Later, more effective treatments for metastatic castrate-resistant prostate cancer may also have had a beneficial impact. Since 2004, the most commonly administered therapy for chemotherapy-naive patients with symptomatic, metastatic castrate-resistant prostate cancer has been docetaxel. 21 Newer treatments that have shown increased survival rates for castrate-resistant prostate cancer, such as abiraterone acetate 22 and enzalutamide, 23 may have influenced mortality rates only in the last couple of years of the study period.
Changes in underlying risk factors. Prior to the PSA era, the observed increase in prostate cancer incidence in all four countries was most probably caused by better access to health care, increasing awareness of prostate-related symptoms and more frequent use of surgical treatment for benign prostate hyperplasia. 24 However, this increase, and the observed variations in incidence and mortality levels across the Nordic countries, may in part be caused by changes over time and by differences between countries in underlying risk factors for disease. In addition to aging, ethnicity and positive family history of prostate cancer, there are few wellestablished risk factors for prostate cancer. A report on prostate cancer from the World Cancer Research Fund concluded that being overweight to some extent increases the risk of advanced prostate cancer, and that developmental factors in the womb, childhood and adolescence that influence growth are linked to increased risk of prostate cancer. 25 However, no single diet or nutritional factor has been conclusively linked to the risk of prostate cancer. Our study cannot assess the effects of possible changes in underlying risk factors. It seems unlikely, however, that the observed decline in mortality across the four countries is driven by favorable changes in risk factors. Breast cancer Increased early diagnostic efforts combined with early effective treatment. In an earlier study, Autier et al. showed that breast cancer mortality reductions were most favorable in women aged 50 and younger. 26 With longer observation times and additional data from Denmark and Finland, the present findings confirm these results. Finland's populationbased breast cancer screening program was gradually introduced from 1987 onwards, beginning with the invitational group aged 50-59 years, and national coverage was achieved in 1992 (Table 6) . 27 In practice, the invitational age has varied considerably across municipalities in Finland, 28 gradually extending since 2007 to women aged 60-69. In Norway, mammography screening for women aged 50-69 years was implemented nationally in 2004, beginning in four of the 19 Norwegian counties in 1995/1996 and gradually expanding. 29 Sweden's screening program was gradually implemented from 1986 onwards, with some variation in invitational age across counties. 30 In Denmark, screening did not extend to most of the country until 2008. 31 While introduction periods and invitational ages for mammography screening have varied across the Nordic countries, screening has been least frequent in the youngest age groups in all four countries. The limited incidence increases in the youngest, as compared to women aged 50-69 years supports this statement; consequently, only minor direct beneficial effects of organized mammography screening are anticipated for mortality trends in the youngest age categories. However, a generally increased awareness in the population including opportunistic screening, better diagnostic procedures and more standardized treatment, partly as indirect effects of the introduction of the screening programs, have most likely been advantageous for even the youngest patients.
In the breast cancer trends, there is no clear relation between incidence increases and mortality reductions. In Sweden, no distinct effect of screening on the age-specific mortality trends can be identified, as the reduction in breast cancer mortality rates among women aged 55-84 years has remained constant since 1975. In contrast, breast cancer mortality rates in Denmark have decreased sharply from the mid-1990s until recently among women aged 75 and younger. The first regional mammography screening program offered from 1991 onwards, covered <20% of the Danish population. 32 The use of diagnostic mammography was also limited in Denmark. 33 Together with the absence of signifi- 35 This led to the recommendation of adjuvant chemotherapy, first for the youngest women. The benefits of these more effective adjuvant treatments, including anthracycline-and taxane-based treatment, were later assessed as having the potential to reduce breast cancer mortality rates by about one-third. 36 More recently, the most important improvements in therapy were the introduction of adjuvant trastuzumab 36 and the use of aromatase inhibitors. 37 First introduced for patients with metastatic disease around 2000, 38 trastuzumab became the standard adjuvant for all women with Her2-positive cancer from 2005. In addition to medical treatment, the use of regional radiotherapy has been shown to increase survival rates and to reduce rate of recurrence. 39 Throughout the almost 40 years covered by our study, Denmark has had the highest breast cancer mortality rates Changes in underlying risk factors. Regardless of Denmark's more limited screening activities, breast cancer incidence rates were higher than in the other countries for almost the entire study period, possibly indicating higher underlying risk of breast cancer. Despite recent improvements, breast cancer mortality rates are still considerably higher in Denmark. The distribution of risk factors for breast cancer across the Nordic countries may have also an impact on mortality levels. Estimates from the international Global Burden of Disease project indicates that about 25% of breast cancer deaths in the Nordic region may be attributable to preventable risk factors such as alcohol consumption, low physical activity and high body mass index. 41 However, only minor changes in these risk estimates have occurred since the 1990s, supporting the assumption that the major proportion of the decline in breast cancer mortality rates is not driven by favorable changes in known risk factors.
Changes in survival
Five-year relative survival estimates for both prostate and breast cancers have increased across all countries and age groups. The abrupt increases in prostate cancer survival from the early to mid-1990s in all countries, and in breast cancer survival among women aged 50-69 years from the mid-1980s in Finland and Sweden, and 10 years later in Norway, coincide with the introduction of PSA testing and mammography screening. These increased survival rates are mirrored by increased incidence, however not by equivalent concurrent reductions in mortality. This indicates that survival estimates around the introduction of new the diagnostic methods are substantially influenced by earlier diagnosis but not necessarily by postponement of death (lead-time bias). Aside from these possible lead-time effects, the increases in survival in women below regular screening age have been parallel to the increases in women aged 50-69 years. These observations are also consistent with the view that other factors beyond the effects of earlier diagnosis are likely to have contributed to the favorable mortality trends from the mid1990s onwards.
Minor improvements in the oldest age groups for both cancers In Denmark, there has been hardly any improvement in prostate or breast cancer mortality rates in the oldest age group; in all four countries, mortality trends are less favorable above 75 years for both cancers. In the oldest age group, this may in part be explained by the fact that not all patients are permanently cured and may die from the disease at an older age. However, the possibility of undertreatment at older ages cannot be excluded. 42 The Danish Breast Cancer Group's treatment protocols did not cover the oldest patients until 2002, and no adjuvant chemotherapy was recommended for patients above 70 years of age before 2007. 43 In Norway, adjuvant treatment is no longer restricted to patients aged under 75 since 2013.
Overdiagnosis
The early diagnostic efforts related to beneficial mortality trends always entails a risk of overdiagnosis. Rates of overdiagnosis have been estimated at around 10-20% for breast cancer and around 30-45% for prostate cancer, depending on the method of estimation. 4, 5 Alongside similar mortality reductions for prostate and breast cancer, prostate cancer incidence rates in Nordic men aged 50-69 have increased by around 300% from the early 1980s while breast cancer incidence rates in Nordic women have increased by 60-140% for the same age group and period. These results suggest that overdetection rates are higher for opportunistic PSA-testing than for organized mammography screening. Incidence of prostate cancer in men aged 70-79 has also increased more rapidly than breast cancer incidence in the same age group. There is very little evidence that PSA testing has any favorable effect on mortality in this age group. 3 Testing of inappropriate age groups with inadequate screening frequency combined with insufficient follow-up after a positive result may reduce the effectiveness of opportunistic screening as compared to organized screening. The possible inferior effectiveness of opportunistic cancer screening as compared to organized approaches has previously been indicated. 44, 45 However, the comparison of breast and prostate cancer incidence trends in relation to overdiagnosis may be somewhat distorted by not considering the increased rates of ductal carcinoma in situ (DCIS) caused by screening. In Norway during the period 1993-2007, there was an observed fourfold increase in age-specific incidence rates of DCIS in women aged 50-69, and in Denmark, detected cases of DCIS more than doubled from 2006 to 2010. 46, 47 Given the uncertainties around the positive effects of treating DCIS, 48 the relative contribution to overdetection and overtreatment may be higher for DCIS than for invasive breast cancer. The rise and fall in use of menopausal hormones may have also influenced breast cancer incidence trends before and after 2000; the strongest decline in the use of such hormones was observed in Sweden and Norway, and may have contributed to the stabilization of incidence rates in these countries post-2000. 49 
Data quality
Although there is uncertainty about the accuracy of cause of death certificates for higher age groups, 7 the relative consistency over time of mortality trends for both cancers across the Nordic countries -at least in younger age groups -is reassuring for the use of national registry data for disease monitoring purposes. However, the abrupt increase in Norwegian mortality trends among men aged 85 and over following the introduction of PSA testing indicates that the peak in mortality around 1996 may in part have been caused by attribution bias. 50 Although Norway had the highest total prostate cancer mortality rates in the Nordic countries in the mid-to late-1990s, the mortality trends in three of the four Nordic countries included in our study have converged in recent years, and the prostate cancer mortality rates for all ages combined are currently almost identical in Denmark, Norway and Sweden. In men aged 75 and younger, Norway currently has the second lowest mortality from prostate cancer of the four (after Finland).
Conclusions
Mortality rates for prostate and breast cancer in the Nordic countries have declined substantially over the last [15] [16] [17] [18] [19] [20] years. The concurrent and continuous increase in incidence rates suggests that the major proportion of this decline in mortality is not driven by favorable changes in risk factors but rather by successful improvements in prostate and breast cancer management, including new treatments, better organization of health care and early diagnostic efforts. Although the relative importance of these measures remains difficult to disentangle, the considerable decrease in breast cancer mortality in the youngest age groups and the early decreases in prostate and breast cancer mortality rates in Denmark below the age of 75, are consistent with favorable contributions from improved treatment in addition to mammography screening and increased PSA testing. Further studies are needed to explain less beneficial changes in mortality in patients aged 75 and older. The large increases in prostate cancer incidence as compared to breast cancer, alongside similar mortality decreases for the two, indicate that a higher proportion of prostate cancer cases are overdiagnosed.
